🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts. 1️⃣ 500 — OPTIMA Test-directed chemotherapy in high-risk ER+/HER2- early BC 2️⃣ LBA1006 — PERSEVERA BC Giredestrant + palbociclib vs letrozole + palbociclib in 1L ER+/HER2- LA/MBC 3️⃣ 507 — KEYNOTE-522 final analysis Perioperative pembrolizumab in high-risk early TNBC 4️⃣ LBA1007 — SERENA-6 1L camizestrant for emergent ESR1 mutations — final PFS2 5️⃣ 502 — LIDERA BC Giredestrant in ER+/HER2- early BC by menopausal status 6️⃣ LBA1000 — ASCENT-04 SG + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC 7️⃣ 501 — NATALEE biomarker analysis Baseline gene expression and adjuvant ribociclib benefit 8️⃣ LBA503 — SENOMAC Omission of axillary dissection: OS + arm morbidity 9️⃣ 1001 — ASCENT-03 SG vs chemotherapy in 1L mTNBC — PFS2 🔟 LBA1003 Izalontamab brengitecan vs physician’s choice chemo in metastatic TNBC Leads🚨 @ElisaAgostinett @to_be_elizabeth @WeOncologists Senior Faculty @ErikaHamilton9 @E_de_Azambuja @matteolambe @DrSGraff @hoperugo @BianchiniGP Dr. Bidard @Icro_Meattini Participating AF @Lucarecco @GaiaGriguolo Ping Faculty @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel
